Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03934372 Recruiting - Lymphoma Clinical Trials

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Start date: January 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

NCT ID: NCT03934060 Completed - Childhood Cancer Clinical Trials

Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients. Increased muscle strength is associated with improved accomplishment of ADLs and consequently greatest possible normality, autonomy and mobility. Primary outcome of this RCT (n=20/20) is the analysis of effects of a treatment-associated and close to every day life strength training (2-3 times/week) compared to a general exercise program (standard care).

NCT ID: NCT03932955 Recruiting - Lymphoma Clinical Trials

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT03932331 Active, not recruiting - Clinical trials for Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Start date: April 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.

NCT ID: NCT03932279 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Start date: January 30, 2019
Phase:
Study type: Observational

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.

NCT ID: NCT03930953 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Start date: May 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

NCT ID: NCT03930043 Recruiting - Clinical trials for Gastrointestinal Lymphoma

A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma Patients

Start date: March 1, 2017
Phase:
Study type: Observational

This is a observational study on the fecal microbiota in primary/secondary gastrointestinal lymphoma patients.

NCT ID: NCT03929107 Recruiting - B Cell Lymphoma Clinical Trials

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.

NCT ID: NCT03927105 Completed - Clinical trials for Peripheral T Cell Lymphoma

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Start date: April 25, 2019
Phase: Phase 2
Study type: Interventional

A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma

NCT ID: NCT03925935 Completed - Hodgkin Lymphoma Clinical Trials

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Start date: May 7, 2019
Phase: Phase 1
Study type: Interventional

A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.